10-Q: Achieve Life Sciences Reports Q1 2025 Results, Highlights Cytisinicline's Regulatory Progress

Achieve Life Sciences reports a net loss of $12.8 million for Q1 2025 while advancing cytisinicline towards NDA submission and Phase 3 vaping cessation trials.

Summary

• Achieve Life Sciences reported a net loss of $12.8 million for the three months ended March 31, 2025, compared to a net loss of $6.5 million for the same period in 2024.
• Research and development expenses increased to $7.1 million, primarily due to the ORCA-OL open-label safety trial.
• General and administrative expenses rose to $5.8 million due to higher employee expenses and commercial launch preparation costs.
• The company's cash, cash equivalents, and marketable securities totaled $23.2 million as of March 31, 2025.
• Substantial doubt exists regarding the company's ability to continue as a going concern, dependent on securing additional financing.
• Achieve plans to submit the cytisinicline NDA to the FDA in June 2025.
• Phase 3 clinical development of cytisinicline for vaping cessation is intended to begin in the first half of 2026, pending funding.
• The ORCA-OL trial reached milestones of 300 subjects completing six months and 100 subjects completing one year of cumulative cytisinicline treatment.
• A dispute exists with Sopharma regarding the potential engagement of third-party manufacturers, which Achieve has proposed steps to resolve.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there is progress in clinical trials and regulatory pathways, the company faces financial challenges and uncertainties regarding future funding and potential disputes.

Positives

• The FDA supports an NDA submission for cytisinicline based on efficacy data from Phase 3 trials.
• The ORCA-OL trial has reached key milestones for safety data collection.
• The Data Safety Monitoring Committee reported no unexpected treatment-related adverse events in the ORCA-OL trial.
• The company has Breakthrough Therapy designation from the FDA for cytisinicline for vaping cessation.
• The company completed an end-of-Phase 2 meeting with the FDA and received guidance on the Phase 3 clinical program for vaping cessation.

Negatives

• The company reported a net loss of $12.8 million for Q1 2025, an increase from $6.5 million in Q1 2024.
• Substantial doubt exists regarding the company's ability to continue as a going concern.
• The company's current resources are insufficient to fund planned operations for the next 12 months.
• A dispute exists with Sopharma regarding the potential engagement of third-party manufacturers.
• The company has no products approved for commercial sale and has not generated any revenue from product sales to date.

Risks

• The company's ability to continue as a going concern is subject to material uncertainty and dependent on obtaining additional financing.
• The development and commercialization of cytisinicline depend on securing sufficient quantities of cytisinicline from trees and other plants.
• There is no guarantee that the FDA will grant marketing approval of cytisinicline without additional clinical or nonclinical studies.
• The company faces substantial competition, and competitors may develop or commercialize products faster or more successfully.
• The company is subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations.

Future Outlook

Achieve plans to submit the cytisinicline NDA to the FDA in June 2025 and intends to initiate Phase 3 clinical development of cytisinicline for vaping cessation in the first half of 2026, dependent on funding.

Management Comments

• Management believes cytisinicline represents a unique opportunity to significantly impact global health by addressing the considerable unmet need among millions of smokers and e-cigarettes users.

Industry Context

The document highlights the significant unmet need in smoking and e-cigarette cessation, noting that tobacco use is the leading cause of preventable death. The company is positioning cytisinicline as a differentiated treatment option with a shorter therapy duration compared to existing treatments.

Comparison to Industry Standards

• The document mentions Pfizer's Chantix (varenicline) halting distribution due to nitrosamine impurities, highlighting the importance of safety and manufacturing standards in the smoking cessation market.
• The company is aiming to provide a new prescription medicine for nicotine dependence, an area that has seen limited innovation in nearly two decades.
• The company is comparing cytisinicline to existing smoking cessation treatments, emphasizing its combination of efficacy, well-tolerated safety profile, and shorter therapy duration.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional financing.
• Employees face uncertainty due to the company's financial situation and potential need to scale back operations.
• Patients may benefit from the potential approval of cytisinicline as a new treatment option for nicotine dependence.
• Suppliers and creditors face the risk of delayed or reduced payments due to the company's financial constraints.

Next Steps

• Submit the cytisinicline NDA to the FDA in June 2025.
• Initiate Phase 3 clinical development of cytisinicline for vaping cessation in the first half of 2026, dependent on funding.
• Continue the ORCA-OL trial and submit safety data with the NDA submission.
• Resolve the dispute with Sopharma regarding the potential engagement of third-party manufacturers.

Key Dates

Keywords

cytisinicline, nicotine dependence, smoking cessation, vaping cessation, clinical trials, FDA, NDA, ORCA-OL, Sopharma, financial results, going concern, regulatory approval